As the co-founder of Biogenity and Omics Studio, my focus is on the intersection of biotechnology and commercial strategy. I specialize in scaling high-tech life science solutions and ensuring that complex omics technologies are accessible and value-driven for our partners in pharma, biotech, and academia.